Search Results - "Beuselinck, Benoit"

Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study by Martínez Chanzá, Nieves, Xie, Wanling, Asim Bilen, Mehmet, Dzimitrowicz, Hannah, Burkart, Jarred, Geynisman, Daniel M, Balakrishnan, Archana, Bowman, I Alex, Jain, Rohit, Stadler, Walter, Zakharia, Yousef, Narayan, Vivek, Beuselinck, Benoit, McKay, Rana R, Tripathi, Abhishek, Pachynski, Russell, Hahn, Andrew W, Hsu, JoAnn, Shah, Sumit A, Lam, Elaine T, Rose, Tracy L, Mega, Anthony E, Vogelzang, Nicholas, Harrison, Michael R, Mortazavi, Amir, Plimack, Elizabeth R, Vaishampayan, Ulka, Hammers, Hans, George, Saby, Haas, Naomi, Agarwal, Neeraj, Pal, Sumanta K, Srinivas, Sandy, Carneiro, Benedito A, Heng, Daniel Y C, Bosse, Dominick, Choueiri, Toni K, Harshman, Lauren C

“…Cabozantinib is approved for patients with metastatic renal cell carcinoma on the basis of studies done in clear-cell histology. The activity of cabozantinib…”
Get full text

First-line Immuno-Oncology Combination Therapies in Metastatic Renal-cell Carcinoma: Results from the International Metastatic Renal-cell Carcinoma Database Consortium by Dudani, Shaan, Graham, Jeffrey, Wells, J. Connor, Bakouny, Ziad, Pal, Sumanta K., Dizman, Nazli, Donskov, Frede, Porta, Camillo, de Velasco, Guillermo, Hansen, Aaron, Iafolla, Marco, Beuselinck, Benoit, Vaishampayan, Ulka N., Wood, Lori A., Liow, Elizabeth, Yan, Flora, Yuasa, Takeshi, Bjarnason, Georg A., Choueiri, Toni K., Heng, Daniel Y.C.

“…In metastatic renal-cell carcinoma (mRCC), recent data have shown efficacy of first-line ipilimumab and nivolumab (ipi-nivo) as well as immuno-oncology…”
Get full text

Trial watch: Dendritic cell (DC)-based immunotherapy for cancer by Laureano, Raquel S, Sprooten, Jenny, Vanmeerbeerk, Isaure, Borras, Daniel M, Govaerts, Jannes, Naulaerts, Stefan, Berneman, Zwi N, Beuselinck, Benoit, Bol, Kalijn F, Borst, Jannie, Coosemans, an, Datsi, Angeliki, Fučíková, Jitka, Kinget, Lisa, Neyns, Bart, Schreibelt, Gerty, Smits, Evelien, Sorg, Rüdiger V, Spisek, Radek, Thielemans, Kris, Tuyaerts, Sandra, De Vleeschouwer, Steven, de Vries, I Jolanda M, Xiao, Yanling, Garg, Abhishek D

“…Dendritic cell (DC)-based vaccination for cancer treatment has seen considerable development over recent decades. However, this field is currently in a state…”
Get full text

Third-line Targeted Therapy in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium by Wells, J. Connor, Stukalin, Igor, Norton, Craig, Srinivas, Sandy, Lee, Jae Lyun, Donskov, Frede, Bjarnason, Georg A, Yamamoto, Haru, Beuselinck, Benoit, Rini, Brian I, Knox, Jennifer J, Agarwal, Neeraj, Ernst, D. Scott, Pal, Sumanta K, Wood, Lori A, Bamias, Aristotelis, Alva, Ajjai S, Kanesvaran, Ravindran, Choueiri, Toni K, Heng, Daniel Y.C

“…Abstract Background The use of third-line targeted therapy (TTT) in metastatic renal cell carcinoma (mRCC) is not well characterized and varies due to the lack…”
Get full text

First-line sunitinib versus pazopanib in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium by Ruiz-Morales, Jose Manuel, Swierkowski, Marcin, Wells, J. Connor, Fraccon, Anna Paola, Pasini, Felice, Donskov, Frede, Bjarnason, Georg A, Lee, Jae-Lyun, Sim, Hao-Wen, Sliwczynsk, Andrzej, Ptak-Chmielewska, Aneta, Teter, Zbigniew, Beuselinck, Benoit, Wood, Lori A, Yuasa, Takeshi, Pezaro, Carmel, Rini, Brian I, Szczylik, Cezary, Choueiri, Toni K, Heng, Daniel Y.C

“…Abstract Background Sunitinib (SU) and pazopanib (PZ) are standards of care for first-line treatment of metastatic renal cell carcinoma (mRCC). However, how…”
Get full text

Trial watch: chemotherapy-induced immunogenic cell death in oncology by Sprooten, Jenny, Laureano, Raquel S., Vanmeerbeek, Isaure, Govaerts, Jannes, Naulaerts, Stefan, Borras, Daniel M., Kinget, Lisa, Fucíková, Jitka, Špíšek, Radek, Jelínková, Lenka Palová, Kepp, Oliver, Kroemer, Guido, Krysko, Dmitri V., Coosemans, An, Vaes, Rianne D.W., De Ruysscher, Dirk, De Vleeschouwer, Steven, Wauters, Els, Smits, Evelien, Tejpar, Sabine, Beuselinck, Benoit, Hatse, Sigrid, Wildiers, Hans, Clement, Paul M., Vandenabeele, Peter, Zitvogel, Laurence, Garg, Abhishek D.

“…Immunogenic cell death (ICD) refers to an immunologically distinct process of regulated cell death that activates, rather than suppresses, innate and adaptive…”
Get full text

Baseline neutrophil-to-eosinophil-ratio and outcome in metastatic clear-cell renal cell carcinoma treated with nivolumab or ipilimumab/nivolumab by Beulque, Yana, Kinget, Lisa, Roussel, Eduard, Mobaraki, Sajedeh, Laenen, Annouschka, Debruyne, Philip R, Van Herck, Yannick, Baldewijns, Marcella, Wozniak, Agnieszka, Garg, Abhishek D, Zucman-Rossi, Jessica, Couchy, Gabrielle, Albersen, Maarten, De Wever, Liesbeth, Haaker, Lorenz, Beuselinck, Benoit

“…This study aims to evaluate neutrophil-to-eosinophil ratio (NER) as a prognostic and/or predictive biomarker in metastatic clear cell renal cell carcinoma…”
Get full text

Unveiling CXCR2 as a promising therapeutic target in renal cell carcinoma: exploring the immunotherapeutic paradigm shift through its inhibition by RCT001 by Montemagno, Christopher, Jacquel, Arnaud, Pandiani, Charlotte, Rastoin, Olivia, Dawaliby, Rosie, Schmitt, Thomas, Bourgoin, Maxence, Palenzuela, Héliciane, Rossi, Anne-Laure, Ambrosetti, Damien, Durivault, Jerome, Luciano, Frederic, Borchiellini, Delphine, Le Du, Julie, Gonçalves, Leticia Christina Pires, Auberger, Patrick, Benhida, Rachid, Kinget, Lisa, Beuselinck, Benoit, Ronco, Cyril, Pagès, Gilles, Dufies, Maeva

“…In clear cell renal cell carcinoma (ccRCC), first-line treatment combines nivolumab (anti-PD-1) and ipilimumab (anti-CTLA4), yielding long-term remissions but…”
Get full text

MicroRNA expression profiles in molecular subtypes of clear-cell renal cell carcinoma are associated with clinical outcome and repression of specific mRNA targets by Verbiest, Annelies, Van Hoef, Vincent, Rodriguez-Antona, Cristina, Garcia-Donas, Jesus, Grana-Castro, Osvaldo, Albersen, Maarten, Baldewijns, Marcella, Laenen, Annouschka, Roussel, Eduard, Schoffski, Patrick, Wozniak, Agnieszka, Caruso, Stefano, Couchy, Gabrielle, Zucman-Rossi, Jessica, Beuselinck, Benoit

“…Clear-cell renal cell carcinomas (ccRCC) can be divided into four transcriptomic subtypes, two of which have a favorable and two an unfavorable prognosis. To…”
Get full text

Impact of concomitant acid suppressive therapy on pazopanib efficacy and dose reductions in patients with metastatic renal cell carcinoma by Van De Sijpe, Greet, Beuselinck, Benoit, Van Nieuwenhuyse, Tine, Poncelet, Roxanne, Bechter, Oliver, Albersen, Maarten, Roussel, Eduard, Baldewijns, Marcella, Tack, Jan, Spriet, Isabel

“…Purpose The aim of this study was to investigate the impact of acid suppressive therapy on clinical efficacy and safety of pazopanib in patients with…”
Get full text

A possible role for microRNA-141 down-regulation in sunitinib resistant metastatic clear cell renal cell carcinoma through induction of epithelial-to-mesenchymal transition and hypoxia resistance by Berkers, Joost, Govaere, Olivier, Wolter, Pascal, Beuselinck, Benoit, Schöffski, Patrick, van Kempen, Léon C, Albersen, Maarten, Van den Oord, Joost, Roskams, Tania, Swinnen, Johan, Joniau, Steven, Van Poppel, Hendrik, Lerut, Evelyne

“…We identified microRNA driven mechanisms in clear cell renal cell carcinoma associated with the tumor response to the multitargeted receptor tyrosine kinase…”
Get more information

Trial watch: anticancer vaccination with dendritic cells by Borges, Francisca, Laureano, Raquel S, Vanmeerbeek, Isaure, Sprooten, Jenny, Demeulenaere, Octavie, Govaerts, Jannes, Kinget, Lisa, Saraswat, Saurabh, Beuselinck, Benoit, De Vleeschouwer, Steven, Clement, Paul, De Smet, Frederik, Sorg, Rüdiger V, Datsi, Angeliki, Vigneron, Nathalie, Naulaerts, Stefan, Garg, Abhishek D

“…Dendritic cells (DCs) are critical players at the intersection of innate and adaptive immunity, making them ideal candidates for anticancer vaccine…”
Get full text

Sunitinib for the treatment of metastatic renal cell carcinoma by Oudard, Stéphane, Beuselinck, Benoit, Decoene, Jasper, Albers, Peter

“…Abstract Sunitinib is an orally administered multitargeted tyrosine kinase inhibitor approved multinationally for the first- and second-line treatment of…”
Get full text

Cabozantinib real‐world effectiveness in the first‐through fourth‐line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium by Gan, Chun Loo, Dudani, Shaan, Wells, J. Connor, Donskov, Frede, Pal, Sumanta K., Dizman, Nazli, Rathi, Nityam, Beuselinck, Benoit, Yan, Flora, Lalani, Aly‐Khan A., Hansen, Aaron, Szabados, Bernadett, Velasco, Guillermo, Tran, Ben, Lee, Jae Lyun, Vaishampayan, Ulka N., Bjarnason, Georg A., Subasri, Mathushan, Choueiri, Toni K., Heng, Daniel Y. C.

“…Background Cabozantinib is approved for metastatic renal cell carcinoma (mRCC) based on the METEOR and CABOSUN trials. However, real‐world effectiveness and…”
Get full text

Baseline circulating unswitched memory B cells and B-cell related soluble factors are associated with overall survival in patients with clear cell renal cell carcinoma treated with nivolumab within the NIVOREN GETUG-AFU 26 study by Carril-Ajuria, Lucia, Desnoyer, Aude, Meylan, Maxime, Dalban, Cécile, Naigeon, Marie, Cassard, Lydie, Vano, Yann, Rioux-Leclercq, Nathalie, Chouaib, Salem, Beuselinck, Benoit, Chabaud, Sylvie, Barros-Monteiro, Janice, Bougoüin, Antoine, Lacroix, Guillaume, Colina-Moreno, Irelka, Tantot, Florence, Boselli, Lisa, De Oliveira, Caroline, Fridman, Wolf Herve, Escudier, Bernard, Sautes-Fridman, Catherine, Albiges, Laurence, Chaput-Gras, Nathalie

“…BackgroundThe phase II NIVOREN GETUG-AFU 26 study reported safety and efficacy of nivolumab in patients with metastatic clear cell renal cell carcinoma…”
Get full text

Multitumor Case Series of Germline BRCA1 , BRCA2 and CHEK2 -Mutated Patients Responding Favorably on Immune Checkpoint Inhibitors by Kinget, Lisa, Bechter, Oliver, Punie, Kevin, Debruyne, Philip R, Brems, Hilde, Clement, Paul, Roussel, Eduard, Van Herck, Yannick, Albersen, Maarten, Baldewijns, Marcella, Schöffski, Patrick, Beuselinck, Benoit

“…In recent years, immune checkpoint inhibitors (ICPI) have become widely used for multiple solid malignancies. Reliable predictive biomarkers for selection of…”
Get full text

Molecular Heterogeneity Between Paired Primary and Metastatic Lesions from Clear Cell Renal Cell Carcinoma by Roussel, Eduard, Kinget, Lisa, Verbiest, Annelies, Zucman-Rossi, Jessica, Boeckx, Bram, Joniau, Steven, Lambrechts, Diether, Albersen, Maarten, Beuselinck, Benoit

“…Highly effective systemic treatments have globally improved outcomes in metastatic clear-cell renal cell carcinoma (m-ccRCC). However, despite many efforts,…”
Get full text

Plk1, upregulated by HIF-2, mediates metastasis and drug resistance of clear cell renal cell carcinoma by Dufies, Maeva, Verbiest, Annelies, Cooley, Lindsay S., Ndiaye, Papa Diogop, He, Xingkang, Nottet, Nicolas, Souleyreau, Wilfried, Hagege, Anais, Torrino, Stephanie, Parola, Julien, Giuliano, Sandy, Borchiellini, Delphine, Schiappa, Renaud, Mograbi, Baharia, Zucman-Rossi, Jessica, Bensalah, Karim, Ravaud, Alain, Auberger, Patrick, Bikfalvi, Andréas, Chamorey, Emmanuel, Rioux-Leclercq, Nathalie, Mazure, Nathalie M., Beuselinck, Benoit, Cao, Yihai, Bernhard, Jean Christophe, Ambrosetti, Damien, Pagès, Gilles

“…Polo-like kinase 1 (Plk1) expression is inversely correlated with survival advantages in many cancers. However, molecular mechanisms that underlie Plk1…”
Get full text

Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category by Davis, Ian D, Xie, Wanling, Pezaro, Carmel, Donskov, Frede, Wells, J. Connor, Agarwal, Neeraj, Srinivas, Sandy, Yuasa, Takeshi, Beuselinck, Benoit, Wood, Lori A, Ernst, D. Scott, Kanesvaran, Ravindran, Knox, Jennifer J, Pantuck, Allan, Saleem, Sadia, Alva, Ajjai, Rini, Brian I, Lee, Jae-Lyun, Choueiri, Toni K, Heng, Daniel Y.C

“…Abstract Background We hypothesized that changes in International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) prognostic category at start of…”
Get full text

Cytoreductive Nephrectomy in Metastatic Papillary Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium by Graham, Jeffrey, Wells, J. Connor, Donskov, Frede, Lee, Jae Lyun, Fraccon, Anna, Pasini, Felice, Porta, Camillo, Bowman, I. Alex, Bjarnason, Georg A., Ernst, D. Scott, Rha, Sun Young, Beuselinck, Benoit, Hansen, Aaron, North, Scott A., Kollmannsberger, Christian K., Wood, Lori A., Vaishampayan, Ulka N., Pal, Sumanta K., Choueiri, Toni K., Heng, Daniel Y.C.

“…There is evidence that cytoreductive nephrectomy (CN) may be beneficial in metastatic renal cell carcinoma (mRCC). This has been studied predominantly in…”
Get full text